Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ (cabozantinib) and has also established a portfolio of other novel compounds, many of which are being advanced by partners as part of collaborations. Michael …Read More
Tag Archives: EXEL
Exelixis, Inc. (NASDAQ: EXEL): COMETRIQ Availability in the U.S.
Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. Exelixis announced on Thursday the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer approved by FDA on November 29, 2012. COMETRIQ (cabozantinib) is being distributed exclusively …Read More